Schrum Private Wealth Management LLC Invests $312,000 in Eli Lilly and Company (NYSE:LLY)

Schrum Private Wealth Management LLC bought a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 352 shares of the company’s stock, valued at approximately $312,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Kovack Advisors Inc. increased its holdings in shares of Eli Lilly and Company by 9.7% in the third quarter. Kovack Advisors Inc. now owns 4,956 shares of the company’s stock worth $4,391,000 after buying an additional 440 shares during the period. Pinnacle Financial Partners Inc lifted its position in Eli Lilly and Company by 0.8% in the third quarter. Pinnacle Financial Partners Inc now owns 35,961 shares of the company’s stock valued at $31,859,000 after purchasing an additional 275 shares during the last quarter. Hartline Investment Corp boosted its stake in shares of Eli Lilly and Company by 33.9% during the third quarter. Hartline Investment Corp now owns 26,958 shares of the company’s stock valued at $23,883,000 after purchasing an additional 6,818 shares during the period. Mengis Capital Management Inc. grew its holdings in shares of Eli Lilly and Company by 2.2% in the third quarter. Mengis Capital Management Inc. now owns 7,559 shares of the company’s stock worth $6,697,000 after purchasing an additional 160 shares during the last quarter. Finally, Simmons Bank increased its stake in shares of Eli Lilly and Company by 1.5% in the third quarter. Simmons Bank now owns 8,409 shares of the company’s stock worth $7,450,000 after buying an additional 121 shares during the period. Institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.13% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on LLY shares. Morgan Stanley reissued an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a report on Monday, September 16th. Deutsche Bank Aktiengesellschaft dropped their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a report on Monday, November 4th. Finally, Sanford C. Bernstein started coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $1,008.41.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $811.30 on Thursday. The firm has a market cap of $770.18 billion, a P/E ratio of 87.71, a PEG ratio of 3.10 and a beta of 0.43. Eli Lilly and Company has a twelve month low of $561.65 and a twelve month high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The company has a 50 day moving average of $891.02 and a 200 day moving average of $870.71.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. During the same quarter in the prior year, the firm earned $0.10 EPS. The firm’s revenue for the quarter was up 20.4% compared to the same quarter last year. As a group, research analysts expect that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.64%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.